Read more
5:50 PM · 23 April 2026

Defence sector earnings: Saab, Safran, Lockheed Martin

The defence industry is gradually wrapping up its earnings season. Thursday will be dominated mainly by Europe’s sector leaders. Against the backdrop of a persistent threat environment and the escalation of armed conflicts worldwide, expectations for companies’ results in this sector are becoming ever higher, and increasingly difficult to meet.

Safran

One of the largest companies in its class. The French aerospace group, in addition to military supplies, also has a large and fast-growing civil segment.
The market reaction suggests the company delivered exactly what investors expected, and that meaningful growth, along with its characteristics, was already priced in.
Revenue rose 18.8% year on year to EUR 8.48bn, slightly beating the market consensus of around EUR 8.3bn.
Segment details were mixed.

  • Revenue in “Equipment & Defense” delivered organic growth of 13.5%, reaching EUR 3.36bn, with “OE” sales up 15.3%.
  • Revenue in propulsion systems grew organically by 33% to EUR 4.5bn, with sales up 35%.
  • The “Aircraft Interiors” segment grew organically by 9.2% (though it is worth noting that in nominal terms it declined) to EUR 700m.

Management confirmed its commitments regarding FY2026 guidance, calling for revenue in the “low teens” (in EUR billions), recurring operating income above EUR 6.1bn, and FCF of at least EUR 4.4bn.

The company also noted it is monitoring the situation in the Middle East and highlighted initial initiatives in the region, such as cooperation with Qatar on building an air-defence system.

SAF.FR (D1)

 

The stock shows high price-change dynamics with high frequency. This may point to equally dynamic shifts in investors’ expectations regarding the company’s outlook, although given the market and geopolitical environment, uncertainty should arguably skew more pro-growth. Source: xStation 5

Saab AB

The Swedish group delivered a very strong quarter, with significant growth and operational optimisation across most areas. However, the market reaction here as well may indicate that much of the growth was already “in the price”. In addition, a decline in orders casts a shadow over the strong results.

  • Orders fell to SEK 18.2bn, translating into an order backlog worth SEK 274bn.
  • Sales revenue increased to SEK 19.2bn, representing organic growth of 23.6%.
  • A particularly positive surprise was operating profit, which rose 32% to SEK 1.92bn, lifting the EBIT margin to 10%.
  • Management pointed to exceptionally strong demand growth for surveillance and monitoring systems. Sales in this segment rose by more than 30%.

SAABB.SE (D1)

 

On the chart, the earnings release coincided with the defence of key levels: the EMA200 moving average and the lower boundary of the long-term upward channel. Source: xStation 5

Lockheed Martin

Expectations for the company were high ahead of the earnings release. On the back of current and anticipated increases in defence spending, shareholders expected Lockheed to justify the more than 40% rise in valuation since the beginning of the year. Investors were looking not only at revenue but also at profitability, the company still has a margin gap to close versus competitors.

  • Revenue expectations were around USD 18.3bn, with EPS of about USD 6.75.

However, the company failed to meet market expectations.

  • Sales revenue came in at only USD 18.0bn.
  • EPS was USD 6.44.
  • This implies net income of USD 1.44bn and an operating margin of 8.9%.

On a segment basis, the disappointment is concentrated in avionics and missiles.

  • The avionics segment posted a year-on-year decline in sales to USD 6.95bn. The company cited losses of USD 325m and a revaluation of F-16 fighter-jet contracts that cost USD 145m. The C-130 program is also causing issues. Ultimately, operating profit in this segment fell 14%.
  • The missiles segment performed better, but given the scale of demand from the U.S. government and allies, growth is well below expectations. Sales revenue rose only 8% to USD 3.64bn. The margin was unchanged at 13.7%.
    • Management highlighted USD 190m in revenue related to expanding production capacity for PAC-3, JASSM, LRASM and PrSM missiles. These munition types currently represent one of the most acute shortages for both the U.S. and NATO as a whole.
  • Rotary-wing aircraft and command-and-control systems is another segment that posted a meaningful decline. Revenue fell to USD 3.9bn, operating profit dropped by more than 20%, and the operating margin slid to 10.6% (previously 12%). The declines stem from a mix of weak sales volumes, internal restructuring, and revaluations of the CH-53K, Seahawk and Black Hawk programs.
  • The space segment picture is mixed. Revenue increased to USD 3.42bn, but operating profit and margins fell by nearly 30%. The company attributed this to low profitability in the commercial/civil initiatives in which it participated.

LMT.US (D1)

 

After paying its dividend in early March, the company lost momentum and reversed trend, falling by around 20% from the local peak. The price only clearly stabilised at the EMA200 moving average. From a technical perspective, to prevent further declines, the stock must at least hold within the consolidation channel between FIBO 68 and FIBO 71; buyers should also aim to defend the EMA200. Source: xStation 5

23 April 2026, 5:27 PM

ServiceNow plunges 13% after earnings 📉Software sell-off kick-off again?

23 April 2026, 5:20 PM

Stock of the Week - Schneider Electric: The Quiet Foundation of the AI and Global Electrification Revolution

23 April 2026, 3:07 PM

Nvidia dominates Big Tech again 🗽 What does the U.S. earnings season show?

23 April 2026, 2:47 PM

Thermo Fisher Scientific slides 3% despite solid financial report 📉

The material on this page does not constitute as financial advice and does not take into account your level of understanding, investment objectives, financial situation or any other particular needs.
All the information provided, including opinions, market research, mathematical results and technical analyses published on the website or transmitted to you by other means is provided for information purposes only and should in no event be interpreted as an offer of, or solicitation for, a transaction in any financial instrument, nor should the information provided be construed as advice of legal or fiscal nature.
Any investment decisions you make shall be based exclusively on your level of understanding, investment objectives, financial situation or any other particular needs. Any decision to act on information published on the website or transmitted to you by other means is entirely at your own risk. You are solely responsible for such decisions.
If you are in doubt or are not sure that you understand a particular product, instrument, service, or transaction, you should seek professional or legal advice before trading.
Investing in OTC Derivatives carries a high degree of risk, as they are leveraged based products and often small movements in the market could lead to much larger movements in the value of your investment and this could work against you or for you. Please ensure that you fully understand the risks involved, taking into account your investments objectives and level of experience, before trading, and if necessary, seek independent advice.